drugset
drugset / Trial / NCT00904852

Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme

NCT00904852 ↗

Phase 1 Withdrawn 30 enrolled Millennium Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a safety study of tandutinib in combination with temozolomide and bevacizumab after people have received radiation therapy and temozolomide treatment. This study will determine the maximum safe dose of tandutinib when combined with temozolomide and bevacizumab and evaluate the safety of the combination treatment.

Timeline

Start
2009-06
Primary completion
2010-05
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 10 mg/kg Intravenous
Subject Tandutinib Small molecule 250 mg Oral
Subject Tandutinib Small molecule 375 mg Oral
Subject Tandutinib Small molecule 500 mg Oral
Subject Tandutinib Small molecule 625 mg Oral
Subject Temozolomide Small molecule 150 mg/m2 Oral

Indications

glioblastoma